Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1625 1629
This examiner grants 80% of resolved cases
John S Kenyon is an examiner in Tech Center 1600 and Art Unit 1622. He has 954 resolved cases. The allowance rate pct is 79.7. This 79.7 allowance rate pct provides a measure of the outcomes for applications on his docket. The 954 resolved cases serve as a basis for evaluating prosecution in Art Unit 1622.
The interview lift pct is 18.3. This 18.3 interview lift pct indicates the correlation between conducting an interview and the probability of an allowance. Practitioners can use the 18.3 figure when deciding whether to engage in verbal advocacy with the examiner. This metric is a component of the data for Tech Center 1600.
The median days to allowance is 857. This 857 median days to allowance represents the time required for an application to reach a grant. The 857 figure is a timeline for the prosecution process from filing to resolution. These metrics provide a view of the examiner's history across the 954 resolved cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18558351 | CRYSTAL FORM IV OF ORGANIC ACID SALTS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND PREPARATION METHOD THEREOF | Non-Final OA | LG CHEM, LTD. |
| 17934277 | Methods Of Treating Chronic Kidney Disease (CKD) With Inhibitors Of Protective Loss-Of-Function Genes | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18696753 | SURFACTANT STABILIZERS | Non-Final OA | NOVARTIS AG |
| 18530467 | COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS | Non-Final OA | Cedars-Sinai Medical Center |
| 18560179 | LIVER X RECEPTOR MODULATORS | Non-Final OA | TRUSTEES OF DARTMOUTH COLLEGE |
| 18396432 | MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME | Final Rejection | University of Maryland, College Park |
| 18560233 | COMBINATION THERAPIES | Non-Final OA | Janssen Pharmaceutica NV |
| 18286677 | PHARMACEUTICAL COMPOSITION COMPRISING NOVEL SD911 COMPOUND AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF TRANSPLANT REJECTION | Non-Final OA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17777910 | TRPM8 MODULATORS | Non-Final OA | Givaudan SA |
| 18552098 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR SIDE EFFECTS OF ANTHRACYCLINE ANTICANCER AGENT | Non-Final OA | Kyushu University, National University Corporation |
| 18389356 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | Non-Final OA | Purdue Pharma L.P. |
| 17798552 | SMALL MOLECULE STING ANTAGONISTS | Non-Final OA | CURADEV PHARMA PVT. LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy